Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus Clear all
Terminated Phase 2 Interventional Results available

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

NCT05879718
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Interventions
Placebo, PF-06823859
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

NCT06013995
View directory record Official record
Conditions
Lupus
Interventions
BMS-986326, Placebo for BMS-986326
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Diego, California • Clearwater, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Not yet recruiting Phase 3 Interventional

A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

NCT07840287
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions
Enpatoran
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Thousand Oaks, California • Cooper City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

NCT07260877
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
Interventions
VENT-03, Placebo
Drug
Lead sponsor
Ventus Therapeutics U.S., Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting Phase 4 Interventional

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 10, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
M5049 low dose, M5049 medium dose, M5049 high dose, Placebo
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 76 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

NCT06625671
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
Interventions
DB-2304, Placebo, Prednisone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
La Palma, California • Clearwater, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 10, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

NCT02847598
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
53
States / cities
Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 10, 2026, 2:38 PM EDT